NCT03040726View on ClinicalTrials.gov

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 3, 2017

Primary Completion Date

February 14, 2022

Study Completion Date

February 14, 2022

Conditions
Malignant NeoplasmNauseaVomiting
Interventions
DRUG

Netupitant

Given PO

DRUG

Palonosetron

Given PO

DRUG

Palonosetron Hydrochloride

Given PO

OTHER

Placebo

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Helsinn Healthcare SA
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Helsinn Healthcare SA

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER